Jidinum (Sitagliptin)

Sitagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally breaks down the incretin hormones GLP‑1 and GIP. By inhibiting DPP‑4, the drug raises endogenous incretin levels, leading to glucose‑dependent insulin release and reduced glucagon secretion after meals, thereby lowering blood sugar.

The appropriate dose of Jidinum is determined by the prescribing clinician based on the patient’s individual clinical profile, including renal function, concomitant medications, and glycaemic targets. Patients should follow the dosage instructions provided by their healthcare provider.

Safety data for sitagliptin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk, and this decision must be made by a qualified physician.

To order Jidinum, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its insulin‑stimulating effect is glucose‑dependent. Unlike GLP‑1 receptor agonists, it is an oral tablet rather than an injectable, but it generally provides a modest reduction in HbA1c and is often used when patients need an additional oral option.

Jidinum should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Jidinum is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the specific administration instructions given by their prescriber.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or breathing difficulties.

Jidinum should be avoided in individuals with known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for patients with severe renal impairment, a history of pancreatitis, or those taking medications that may cause significant drug‑drug interactions without proper monitoring.